Document Detail

Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
MedLine Citation:
PMID:  18214064     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Non-small cell lung cancer (NSCLC) remains a highly lethal disease worldwide and research for more effective treatment strategies is ongoing. Identification of molecular prognostic and predictive markers remains under investigation with results that are often conflicting. PATIENTS AND METHODS: Seventy-three patients (n= 73) with stage IB-IIIA completely resected NSCLC who were postoperatively treated with 6 cycles of paclitaxel and carboplatin from July 1998 to September 2002 took part in this study. Most stage IIIA patients subsequently received adjuvant radiotherapy. Cyclooxygenase-2 (COX-2), vascular endorhelial growth factor (VEGF), dihydrodiol dehydrogenase (DDH), receptor-binding cancer antigen expressed on SiSo cells (RCAS-1) and epidermic growth factor receptor (EGFR/HER-1) expression were assessed immunohistochemically; Heregulin family (HER1-4), VEGF and p53 were analysed by RT-PCR. RESULTS: Totally, 61 (84%) men and 12 (16%) women with median age of 63 years and median PS of 0 were included in the study. There were 18 stage IB, 29 stage II and 26 stage IIIA patients. Sixty-seven samples were available for immunohistohemistry. COX-2 expression was detected in 24 patients (36%), VEGF in 14 (21%), RCAS1 in 31 (46%), DDH in 15 (22%). For EGFR, only 58 samples were evaluated, 13 of which were positive (22%). Messenger RNA expression data was only available for 60 patients; VEGF was detected in 32 (53%), p53 in 30 (50%), EGFR in 35 (58%), HER2 in 4 (7%) and HER3 in 19 (32%). HER4 was not detected in any sample. In the Cox analysis for overall survival (OS) and disease-free survival (DFS), none of the factors evaluated by IHC or RT-PCR reached statistical significance. CONCLUSION: Even though the biomarkers tested are expressed in a significant proportion of lung tumors, none of them was found to be of prognostic significance in patients with NSCLC.
Eleni Timotheadou; Dimosthenis-Vasilios Skarlos; Epaminondas Samantas; Savvas Papadopoulos; Sam Murray; Jana Skrickova; Christos Christodoulou; Christos Papakostantinou; Dimitrios Pectasides; Pavlos Papakostas; Jana Kaplanova; Eleni Vrettou; Maria Karina; Paraskevas Kosmidis; George Fountzilas
Related Documents :
16847764 - Clinical significance of cyclooxygenase-2 (cox-2) in multiple myeloma.
19554504 - Expression of hexokinases and glucose transporters in treated and untreated oesophageal...
11751504 - Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovaria...
11820564 - Tissue expression of vegf as a prognostic factor in early cervical squamous cell carcin...
9342254 - Predictors of survival in hiv-infected persons with 50 or fewer cd4 cells/mm3.
8083714 - Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transpl...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  27     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2007 Nov-Dec
Date Detail:
Created Date:  2008-01-24     Completed Date:  2008-02-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  4481-9     Citation Subset:  IM    
Department of Medical Oncology, Papageorgiou General Hospital, Aristotle University of Thessaloniki School of Medicine, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carboplatin / administration & dosage
Carcinoma, Non-Small-Cell Lung / metabolism*,  pathology*,  therapy
Combined Modality Therapy
Disease-Free Survival
Kaplan-Meiers Estimate
Lung Neoplasms / metabolism*,  pathology*,  therapy
Middle Aged
Neoplasm Staging
Paclitaxel / administration & dosage
Radiotherapy, Adjuvant
Reverse Transcriptase Polymerase Chain Reaction
Tumor Markers, Biological / analysis*
Reg. No./Substance:
0/Tumor Markers, Biological; 33069-62-4/Paclitaxel; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human papillomavirus (HPV), DNA aberrations and cell cycle progression in anal squamous cell carcino...
Next Document:  Verrucous carcinoma of the cervix: detection of carcinogenetic human papillomavirus types and their ...